Moreover, low-dose bortezomib augmented the presence of NKG2D and DNAM-1 ligands on MM cells, which increased the sensitivity of MM cells to the cytotoxic effects of γδ T cells. This evidence concerns the gene KLRK1 and Miyoshi myopathy.